<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03331432</url>
  </required_header>
  <id_info>
    <org_study_id>1203573</org_study_id>
    <nct_id>NCT03331432</nct_id>
  </id_info>
  <brief_title>Effects of Dietary Supplement Tauroursodeoxycholic Acid on Vascular Function</brief_title>
  <official_title>Targeting Endoplasmic Reticulum Stress to Correct Vascular Insulin Resistance and Glycemic Dysregulation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Missouri-Columbia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Missouri-Columbia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the present study is to determine if use of dietary supplement
      tauroursodeoxycholic acid enhances insulin-stimulated leg blood flow and glucose disposal.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The notion that cellular stress lowers insulin-induced vasodilation is largely founded on ex
      vivo studies and experiments in rodents. However, it remains unknown if maintenance of
      cellular function with the use of dietary supplement tauroursodeoxycholic acid enhances
      vascular function in humans. The investigators test the hypothesis that daily administration
      of this dietary supplement enhances vascular function, particularly, insulin-stimulated leg
      blood flow and glucose disposal.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 28, 2015</start_date>
  <completion_date type="Actual">February 14, 2018</completion_date>
  <primary_completion_date type="Actual">August 15, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Single-blinded randomized crossover study</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Participants are not told which are placebo or tauroursodeoxycholic acid capsules</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Blood flow</measure>
    <time_frame>Once at 4 weeks after the start of placebo and once at 4 weeks after the start of tauroursodeoxycholic acid</time_frame>
    <description>Blood flow response during insulin clamp</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vascular function</measure>
    <time_frame>Once at 4 weeks after the start of placebo and once at 4 weeks after the start of tauroursodeoxycholic acid</time_frame>
    <description>Flow-mediated dilation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Insulin resistance</measure>
    <time_frame>Once at 4 weeks after the start of placebo and once at 4 weeks after the start of tauroursodeoxycholic acid</time_frame>
    <description>Glucose disposal rate during insulin clamp</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Glucose tolerance</measure>
    <time_frame>Once at 4 weeks after the start of placebo and once at 4 weeks after the start of tauroursodeoxycholic acid</time_frame>
    <description>Glucose response to an oral glucose tolerance test</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Taking daily placebo capsules for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tauroursodeoxycholic acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Taking tauroursodeoxycholic acid (1750 mg/day) capsules for 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Tauroursodeoxycholic acid</intervention_name>
    <description>Taking tauroursodeoxycholic acid (1750 mg/day) capsules for 4 weeks.</description>
    <arm_group_label>Tauroursodeoxycholic acid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Taking daily placebo capsules for 4 weeks.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 diabetes diagnosed by primary physician

          -  Body mass index less then 43 kg/m2

        Exclusion Criteria:

          -  Recent weight gain or loss (&gt;5% body weight in the last 3 months)

          -  Pregnancy

          -  Consumption of &gt;14 alcoholic beverages per week

          -  Changes in the medication use or dose within the last 3 months

          -  Known cardiovascular or pulmonary disease

          -  Taking medication for advanced retinopathy or neuropathy

          -  Taking prescription anticoagulants

          -  Nicotine use
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jaume Padilla, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Missouri-Columbia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Missouri</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 26, 2017</study_first_submitted>
  <study_first_submitted_qc>October 31, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2017</study_first_posted>
  <last_update_submitted>February 14, 2018</last_update_submitted>
  <last_update_submitted_qc>February 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Missouri-Columbia</investigator_affiliation>
    <investigator_full_name>Jaume Padilla</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tauroursodeoxycholic acid</mesh_term>
    <mesh_term>Taurochenodeoxycholic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

